Abstract
Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently presented as the physiologic antagonist of thromboxane A2 (TXA2), which exhibits pro-aggregatory and vasoconstrictor properties. So, the balance between PGI2 and TXA2 production is crucial for the cardiovascular system. Indeed, an imbalance in the production or effect of these products is deleterious for the circulatory system and can lead to characterized vascular diseases such as hypertension, stroke, atherosclerosis or myocardial infarction. Although the biological effects of PGI2 are considered to be clinically useful, its use as therapeutic agent is largely limited by both its chemical and metabolic instability. Actually, several prostacyclin agonists have been synthesized and pharmacologically evaluated. Among these, some have been clinically evaluated as therapeutic agents in several vascular diseases. This review focuses on the latest chemical and pharmacological developments in the field of the prostacyclin agonists.
Keywords: thromboxane, prostacyclin modulators, prostacyclin, hypertension, stroke, atherosclerosis, myocardial infarction
Current Medicinal Chemistry
Title: New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators
Volume: 11 Issue: 10
Author(s): Xavier de Leval, Julien Hanson, Jean-Louis David, Bernard Masereel, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Keywords: thromboxane, prostacyclin modulators, prostacyclin, hypertension, stroke, atherosclerosis, myocardial infarction
Abstract: Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet function and possesses a strong vasodilator effect. Furthermore, prostacyclin is currently presented as the physiologic antagonist of thromboxane A2 (TXA2), which exhibits pro-aggregatory and vasoconstrictor properties. So, the balance between PGI2 and TXA2 production is crucial for the cardiovascular system. Indeed, an imbalance in the production or effect of these products is deleterious for the circulatory system and can lead to characterized vascular diseases such as hypertension, stroke, atherosclerosis or myocardial infarction. Although the biological effects of PGI2 are considered to be clinically useful, its use as therapeutic agent is largely limited by both its chemical and metabolic instability. Actually, several prostacyclin agonists have been synthesized and pharmacologically evaluated. Among these, some have been clinically evaluated as therapeutic agents in several vascular diseases. This review focuses on the latest chemical and pharmacological developments in the field of the prostacyclin agonists.
Export Options
About this article
Cite this article as:
Leval de Xavier, Hanson Julien, David Jean-Louis, Masereel Bernard, Pirotte Bernard and Dogne Jean-Michel, New Developments on Thromboxane and Prostacyclin Modulators Part II: Prostacyclin Modulators, Current Medicinal Chemistry 2004; 11 (10) . https://dx.doi.org/10.2174/0929867043365279
DOI https://dx.doi.org/10.2174/0929867043365279 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Renal Endothelial Dysfunction in Diabetic Nephropathy
Cardiovascular & Hematological Disorders-Drug Targets The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Neuroprotection by (endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases
Current Neuropharmacology Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future
Current Pharmaceutical Design Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Interleukin-19 as an Immunoregulatory Cytokine
Current Molecular Pharmacology Role of Reactive Oxygen Species in Tumor Necrosis Factor-alpha Induced Endothelial Dysfunction
Current Hypertension Reviews Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Current Medicinal Chemistry Editorial [Hot topic: Modifying Cardiovascular Risk Factors: Epidemiology and Characteristics of Smoking-Related Cardiovascular Diseases (Executive Editor: Aurelio Leone)]
Current Pharmaceutical Design Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Acute Phase Proteins In Atherosclerosis (Acute Coronary Syndrome)
Cardiovascular & Hematological Agents in Medicinal Chemistry Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
Current Pharmaceutical Design Vascular Changes of the Retina and Choroid in Systemic Lupus Erythematosus: Pathology and Pathogenesis
Current Neurovascular Research The Role of Metabolism in Toxicity of Polycyclic Aromatic Hydrocarbons and their Non-genotoxic Modes of Action
Current Drug Metabolism Therapeutic Prospects of PPARs in Psychiatric Disorders: A Comprehensive Review
Current Drug Targets Secondary Stroke Prevention with Antithrombotic Drugs
Current Vascular Pharmacology